Payers and providers play an important role in addressing the opioid crisis in our communities. This page highlights the most recently added resources specifically targeting healthcare providers, healthcare system employees, and individuals who manage private and public insurance plans. These resources, identified with blue tiles, include patient and provider education materials, clinical practice guidelines and practice protocols, and research and reports about insurance coverage and benefit design around addiction treatment and pain management.
If you’d like to submit materials for inclusion consideration or suggest a future featured topic, please visit CLOUD’s call for submissions page.
This report describes a complex care management program for pregnant women with a diagnosis of substance use disorder in Camden, New Jersey. The program, called Camden Delivers, enrolled 46 pregnant or postpartum women who were involved with the child welfare system into the care management program.
The Biden-Harris Administration’s statement of drug policy describes the 7 priorities for the first year of their administration:
This resource describes successful models states and localities have put into use to address mental health, substance use, homelessness and children’s services in order to reduce law enforcement involvement.
These supplementary materials accompany the Veterans Administration’s systematic review of transcranial magnetic stimulation (TMS) for chronic pain, post-traumatic stress disorder, traumatic brain injury, and opiate addiction.
The Veterans Administration’s Evidence Synthesis Program prepared this systematic review on the effectiveness of transcranial magnetic stimulation (TMS) to reduce symptoms in people with chronic pain, post-traumatic stress disorder, traumatic brain injury, and opiate addiction at the request from the Center for Compassionate Care Innovation.
This report details how the opioid crisis has affected the Hispanic/Latino population in the US. It includes data on opioid use in this community and a discussion of the socio-cultural factors associated with accessing services including facilitators and barriers to accessing appropriate prevention, treatment, and recovery services and supports.
The New Mexico statewide standing order authorizes registered pharmacists in the state to dispense naloxone to any person who uses an opioid, regardless of how the opioid is used or obtained, or to any person in a position to assist a person at risk of experiencing an opioid overdose.
The Substance Abuse and Mental Health Services Administration and the Centers for Disease Control and Prevention announced that federal funding may be used to purchase rapid fentanyl test strips (FTS). FTS can be used to determine if drugs have been cut or mixed with fentanyl which greatly increases the risk of overdose death.
In April 2021, the FDA announced approval of an application for a produce to deliver an 8 milligram (mg) dose of naloxone; previous approvals had been granted for products delivering 2 mg and 4 mg of naloxone. The approval was granted to provide an additional option for the treatment of opioid overdose.
This resource supports successful planning, design, implementation, and sustainability of syringe service programs (SSPs). The document describes 5 main strategies for SSP implementation and service delivery that are know to be effective: